Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
$0.12
$0.16
$0.09
$3.39
$997K-0.06182,361 shs18,611 shs
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
$0.00
$0.07
$6.56
$1.04M1.36315,915 shsN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$0.03
-1.8%
$0.03
$0.02
$16.25
$857K1.564.98 million shs260,246 shs
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
$0.68
-55.8%
$0.68
$0.50
$160.00
$279K0.01177,918 shs5.33 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00%-7.83%-22.58%-33.33%-92.00%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00%0.00%-99.72%-99.72%-81.82%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
0.00%-10.13%-8.03%-29.49%-99.68%
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
0.00%0.00%0.00%0.00%-99.01%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.8774 of 5 stars
0.05.00.00.00.60.01.3
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/AN/AN/AN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
1.5341 of 5 stars
3.50.00.00.00.60.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.00
N/AN/AN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
0.00
N/AN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
0.00
N/AN/AN/A
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
3.00
Buy$48.006,948.46% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/A$0.71 per shareN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/A$0.19 per shareN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$5.11M0.17N/AN/A$4.04 per share0.01
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
$4.76M0.06N/AN/A$519.58 per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
-$16.08MN/A0.00N/AN/AN/A-2,842.40%-337.48%N/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
-$43.77M-$3.46N/AN/AN/AN/A-584.97%-159.45%N/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
-$8.16M-$52.91N/AN/AN/A-78.22%-23.50%N/A
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
-$7.35MN/A0.00N/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/AN/AN/AN/AN/A
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/AN/AN/AN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
N/AN/AN/AN/AN/A
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
N/A
0.86
0.86
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
N/A
0.59
0.59
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
1.58
0.85
0.74
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
0.67
1.12
N/A

Institutional Ownership

CompanyInstitutional Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
5.74%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
22.34%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
12.34%
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
16.25%

Insider Ownership

CompanyInsider Ownership
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
0.72%
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
2.40%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
12.25%
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
15.44%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bio-Path Holdings, Inc. stock logo
BPTH
Bio-Path
108.31 million5.73 millionOptionable
9 Meters Biopharma, Inc. stock logo
NMTR
9 Meters Biopharma
2014.34 million13.99 millionNo Data
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
2031.16 million9.93 millionNot Optionable
TC Biopharm (Holdings) Plc stock logo
TCBP
TC Biopharm
80410,00028,000Not Optionable

Recent News About These Companies

TC BioPharm Holdings PLC (TCBPY)
TC Biopharm announces transition to OTC Markets from Nasdaq
TCBP Announces Transition from Nasdaq to OTC Markets
TC Biopharm launches cost reduction initiatives
TC Falls Despite Cohort B Trials

New MarketBeat Followers Over Time

Bio-Path stock logo

Bio-Path NASDAQ:BPTH

$0.12 0.00 (0.00%)
As of 08/22/2025 03:00 PM Eastern

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.

9 Meters Biopharma stock logo

9 Meters Biopharma NASDAQ:NMTR

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.

Petros Pharmaceuticals stock logo

Petros Pharmaceuticals NASDAQ:PTPI

$0.03 0.00 (-1.79%)
As of 08/22/2025 03:54 PM Eastern

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

TC Biopharm stock logo

TC Biopharm NASDAQ:TCBP

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.